Expression of TNF-superfamily members BAFF and APRIL in breast cancer: Immunohistochemical study in 52 invasive ductal breast carcinomas
Creators
- 1. Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, 71003 (Greece)
- 2. Department of Pathology, University of Crete, School of Medicine, Heraklion, 71003 (Greece)
- 3. Department of Surgical Oncology, University of Crete, School of Medicine, Heraklion, 71003 (Greece)
- 4. INSERM, Unité 841, Faculté de Medécine, Université de Paris 12, Créteil, 94010 (France)
Description
Recent studies suggest an association between chronic inflammation, modulating the tissue microenvironment, and tumor biology. Tumor environment consists of tumor, stromal and endothelial cells and infiltrating macrophages, T lymphocytes, and dendritic cells, producing an array of cytokines, chemokines and growth factors, accounting for a complex cell interaction and regulation of differentiation, activation, function and survival of tumor and surrounding cells, responsible for tumor progression and spreading or induction of antitumor immune responses and rejection. Tumor Necrosis Factor (TNF) family members (19 ligands and 29 receptors) represent a pleiotropic family of agents, related to a plethora of cellular events from proliferation and differentiation to apoptosis and tumor reduction. Among these members, BAFF and APRIL (CD257 and CD256 respectively) gained an increased interest, in view of their role in cell protection, differentiation and growth, in a number of lymphocyte, epithelial and mesenchymal structures. We have assayed by immunohistochemistry 52 human breast cancer biopsies for the expression of BAFF and APRIL and correlated our findings with clinicopathological data and the evolution of the disease. BAFF was ubiquitely expressed in breast carcinoma cells, DCIS, normal-appearing glands and ducts and peritumoral adipocytes. In contrast, APRIL immunoreactive expression was higher in non-malignant as compared to malignant breast structures. APRIL but not BAFF immunoreactivity was higher in N+ tumors, and was inversely related with the grade of the tumors. Neither parameter was related to DFS or the OS of patients. Our data show, for the first time, an autocrine secretion of BAFF and APRIL from breast cancer cells, offering new perspectives for their role in neoplastic and normal breast cell biology and offering new perspectives for possible selective intervention in breast cancer
Availability note (English)
Available from http://dx.doi.org/10.1186/1471-2407-8-76; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323393Additional details
Identifiers
Publishing Information
- Journal Title
- BMC cancer (Online)
- Journal Volume
- 8
- Journal Page Range
- p. 76
- ISSN
- 1471-2407
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 46091912
- Subject category
- S60: APPLIED LIFE SCIENCES; S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- APOPTOSIS; BIOPSY; CARCINOMAS; ENVIRONMENT; INFLAMMATION; INTERACTIONS; LYMPHOCYTES; LYMPHOKINES; MACROPHAGES; MAMMARY GLANDS; NEOPLASMS; PATIENTS; RECEPTORS; SAFETY
- Descriptors DEC
- ANIMAL CELLS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY; BODY FLUIDS; CONNECTIVE TISSUE CELLS; DIAGNOSTIC TECHNIQUES; DISEASES; GLANDS; GROWTH FACTORS; LEUKOCYTES; MATERIALS; MEMBRANE PROTEINS; MITOGENS; NEOPLASMS; ORGANIC COMPOUNDS; ORGANS; PATHOLOGICAL CHANGES; PHAGOCYTES; PROTEINS; SOMATIC CELLS; SYMPTOMS
Optional Information
- Copyright
- Copyright (c) 2008 Pelekanou et al
- Notes
- PMCID: PMC2323393; PUBLISHER-ID: 1471-2407-8-76; PMID: 18366696; OAI: oai:pubmedcentral.nih.gov:2323393; licensee BioMed Central Ltd.